Our competitor Ovid Therapeutics fails a major study of Angelman Syndrome with OV101 ( phase 2 even fragile x):
https://investors.ovidrx.com/news-r...nnounces-phase-3-neptune-clinical-trial-ov101
https://ovidrx.com/science/pipeline/
OVID FAIL
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.59 |
Change
-0.160(1.16%) |
Mkt cap ! $1.762B | |||
| Open | High | Low | Value | Volume |
| $13.85 | $14.08 | $13.46 | $2.692M | 196.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 667 | $13.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.59 | 120 | 3 |
View Market Depth
| Last trade - 11.52am 10/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |